ArticleDermatology practical & conceptual2025
Serum Endoglin and Endocan Levels in Rosacea and Their Association with Cardiovascular Risk Factors: A Case-Control Study.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRosacea, a chronic skin disease characterized by facial redness, is believed to involve inflammation and angiogenesis in its pathogenesis. Endocan and endoglin, biomarkers associated with vascular and inflammatory processes, might play roles in rosacea and cardiovascular comorbidities.
objectivesThis study aimed to assess serum levels of endocan and endoglin in individuals with rosacea and the function of these biomarkers in indicating comorbidities associated with rosacea.
methodsA total of forty-four patients diagnosed with rosacea and thirty-three healthy controls were included in this case-control study. The endocan and endoglin levels in serum samples from both groups were measured.
resultsNo significant difference in endocan and endoglin levels was observed between the patient and control groups. However, their levels were associated with various clinical features, including symptom and disease severity. A notable association was identified between waist circumference, body mass index, and endoglin levels. However, this association was not evident for endocan.
conclusionsThis study suggests endocan and endoglin may play roles in rosacea pathogenesis, with endoglin potentially associated with increased cardiovascular risk.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.